After years of promise, multiplexing technology has matured from a research tool to a critical selection device, driven by several late-stage clinical programs. The integration of advanced staining reagents, digital quantification, and sophisticated controls with calibrated systems has significantly enhanced the accuracy and reproducibility of multiplexed assays. These technological advancements have revolutionized the ability to measure and analyze multiple biomarkers simultaneously, offering a powerful approach to understanding complex tumor biology and therapeutic responses.

 

As the field of targeted therapies continues to evolve, particularly with the rise of Antibody-Drug Conjugates (ADCs) and Immuno-Oncology (IO) therapies, this evolution in multiplexing technology is poised to play a pivotal role in improving clinical trial outcomes and patient care.

 

By enabling more precise selection and monitoring of patient cohorts, multiplexing can:

This webinar will explore how these advancements in multiplexing can directly contribute to better, more personalized cancer therapies and improve the future of oncology clinical trials.